PSTX - Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08 revenue of $2.7M beats by $1.77M August, 11 2022 05:41 PM Poseida Therapeutics Inc. Poseida Therapeutics press release ( NASDAQ: PSTX ): Q2 GAAP EPS of -$0.69 beats by $0.08 . Revenue of $2.7M beats by $1.77M . For further details see: Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M